🇺🇸 FDA
Patent

US 11680254

Engineered meganucleases specific for recognition sequences in the PCSK9 gene

granted A61KA61K38/00A61K48/00

Quick answer

US patent 11680254 (Engineered meganucleases specific for recognition sequences in the PCSK9 gene) held by Precision BioSciences, Inc. expires Mon Jun 15 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Precision BioSciences, Inc.
Grant date
Tue Jun 20 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 15 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
8
CPC classes
A61K, A61K38/00, A61K48/00